Julian Downward

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3511670/publications.pdf

Version: 2024-02-01

220 papers	49,960 citations	3668 92 h-index	1834 216 g-index
231 all docs	231 docs citations	231 times ranked	52157 citing authors

#	Article	IF	Citations
1	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. New England Journal of Medicine, 2012, 366, 883-892.	13.9	6,769
2	Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer, 2003, 3, 11-22.	12.8	2,800
3	Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature, 1984, 309, 418-425.	13.7	2,759
4	Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature, 1984, 307, 521-527.	13.7	2,604
5	Phosphatidylinositol-3-OH kinase direct target of Ras. Nature, 1994, 370, 527-532.	13.7	1,886
6	Mechanisms and consequences of activation of protein kinase B/Akt. Current Opinion in Cell Biology, 1998, 10, 262-267.	2.6	1,222
7	Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature, 1997, 385, 544-548.	13.7	1,114
8	Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell, 1993, 73, 611-620.	13.5	1,082
9	Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras. Cell, 1997, 89, 457-467.	13.5	1,007
10	Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO Journal, 1997, 16, 2783-2793.	3.5	936
11	Stimulation of p21ras upon T-cell activation. Nature, 1990, 346, 719-723.	13.7	907
12	Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature, 1993, 364, 352-355.	13.7	723
13	Akt Phosphorylates the Yes-Associated Protein, YAP, to Induce Interaction with 14-3-3 and Attenuation of p73-Mediated Apoptosis. Molecular Cell, 2003, 11, 11-23.	4.5	723
14	Autophosphorylation sites on the epidermal growth factor receptor. Nature, 1984, 311, 483-485.	13.7	703
15	PI 3-kinase, Akt and cell survival. Seminars in Cell and Developmental Biology, 2004, 15, 177-182.	2.3	698
16	Ras and TGFÎ² cooperatively regulate epithelial cell plasticity and metastasis. Journal of Cell Biology, 2002, 156, 299-314.	2.3	684
17	Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature, 1992, 356, 713-715.	13.7	653
18	PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends in Biochemical Sciences, 1997, 22, 355-358.	3.7	650

#	Article	IF	Citations
19	Expression cloning and characterization of the TGF-Î² type III receptor. Cell, 1991, 67, 797-805.	13.5	625
20	PINK1-Associated Parkinson's Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death. Molecular Cell, 2009, 33, 627-638.	4.5	584
21	RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes and Cancer, 2011, 2, 261-274.	0.6	580
22	Binding of Ras to Phosphoinositide 3-Kinase p110Î± Is Required for Ras- Driven Tumorigenesis in Mice. Cell, 2007, 129, 957-968.	13.5	524
23	Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Human Molecular Genetics, 2005, 14, 2099-2111.	1.4	514
24	Ras signalling and apoptosis. Current Opinion in Genetics and Development, 1998, 8, 49-54.	1.5	508
25	The Serine Protease Omi/HtrA2 Regulates Apoptosis by Binding XIAP through a Reaper-like Motif. Journal of Biological Chemistry, 2002, 277, 439-444.	1.6	470
26	Navigating gene expression using microarrays â€" a technology review. Nature Cell Biology, 2001, 3, E190-E195.	4.6	460
27	Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity, 2017, 47, 1083-1099.e6.	6.6	450
28	The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nature Cell Biology, 2007, 9, 1243-1252.	4.6	441
29	Minimizing the risk of reporting false positives in large-scale RNAi screens. Nature Methods, 2006, 3, 777-779.	9.0	417
30	Chromosomal Instability Confers Intrinsic Multidrug Resistance. Cancer Research, 2011, 71, 1858-1870.	0.4	391
31	PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene, 2005, 24, 6465-6481.	2.6	383
32	Multiple Ras Effector Pathways Contribute to G1Cell Cycle Progression. Journal of Biological Chemistry, 1999, 274, 22033-22040.	1.6	368
33	Neuroprotective Role of the Reaper-Related Serine Protease HtrA2/Omi Revealed by Targeted Deletion in Mice. Molecular and Cellular Biology, 2004, 24, 9848-9862.	1.1	367
34	Regulators of Mitotic Arrest and Ceramide Metabolism Are Determinants of Sensitivity to Paclitaxel and Other Chemotherapeutic Drugs. Cancer Cell, 2007, 11, 498-512.	7.7	351
35	Akt/PKB localisation and 3â€² phosphoinositide generation at sites of epithelial cellâ€"matrix and cellâ€"cell interaction. Current Biology, 1999, 9, 433-436.	1.8	295
36	PINK1 Is Necessary for Long Term Survival and Mitochondrial Function in Human Dopaminergic Neurons. PLoS ONE, 2008, 3, e2455.	1.1	273

#	Article	IF	Citations
37	Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes and Development, 2000, 14, 2610-2622.	2.7	270
38	Identification of Novel Isoforms of the BH3 Domain Protein Bim Which Directly Activate Bax To Trigger Apoptosis. Molecular and Cellular Biology, 2002, 22, 3577-3589.	1.1	267
39	Role of Phosphoinositide 3-Kinase in Activation of Ras and Mitogen-Activated Protein Kinase by Epidermal Growth Factor. Molecular and Cellular Biology, 1999, 19, 4279-4288.	1.1	258
40	Intramolecular and Intermolecular Interactions of Protein Kinase B Define Its Activation In Vivo. PLoS Biology, 2007, 5, e95.	2.6	254
41	HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature, 2014, 505, 212-217.	13.7	253
42	The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer. Cell, 2012, 149, 642-655.	13.5	247
43	Chromosomal instability determines taxane response. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8671-8676.	3.3	244
44	RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms. Cell, 2013, 153, 1050-1063.	13.5	244
45	The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene, 2018, 37, 5435-5450.	2.6	239
46	Analysis of the transcriptional program induced by Raf in epithelial cells. Genes and Development, 2001, 15, 981-994.	2.7	222
47	The ins and outs of signalling. Nature, 2001, 411, 759-762.	13.7	213
48	R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Current Biology, 1997, 7, 63-71.	1.8	211
49	The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel. Cancer Cell, 2007, 12, 514-527.	7.7	202
50	How BAD phosphorylation is good for survival. Nature Cell Biology, 1999, 1, E33-E35.	4.6	201
51	Phosphoinositide 3-Kinase Induces Scattering and Tubulogenesis in Epithelial Cells through a Novel Pathway. Journal of Biological Chemistry, 1998, 273, 18793-18801.	1.6	199
52	Vav1 Transduces T Cell Receptor Signals to the Activation of Phospholipase C-Î³1 via Phosphoinositide 3-Kinase-dependent and -independent Pathways. Journal of Experimental Medicine, 2002, 195, 1103-1114.	4.2	199
53	Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis. Current Biology, 1999, 9, 1043-S2.	1.8	193
54	Lipid-Regulated Kinases: Some Common Themes at Last. Science, 1998, 279, 673-674.	6.0	189

#	Article	IF	Citations
55	Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer. Cancer Discovery, 2014, 4, 606-619.	7.7	183
56	FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCÉ›, B-Raf and S6K2. EMBO Journal, 2006, 25, 3078-3088.	3.5	173
57	The Tumor Suppressor RASSF1A and MAP-1 Link Death Receptor Signaling to Bax Conformational Change and Cell Death. Molecular Cell, 2005, 18, 637-650.	4.5	166
58	The ras superfamily of small GTP-binding proteins. Trends in Biochemical Sciences, 1990, 15, 469-472.	3.7	165
59	CUTL1 is a target of TGFÎ² signaling that enhances cancer cell motility and invasiveness. Cancer Cell, 2005, 7, 521-532.	7.7	161
60	The GRB2/Sem-5 adaptor protein. FEBS Letters, 1994, 338, 113-117.	1.3	160
61	Induction of Mxi1-SRÎ± by FOXO3a Contributes to Repression of Myc-Dependent Gene Expression. Molecular and Cellular Biology, 2007, 27, 4917-4930.	1.1	158
62	Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Research, 2012, 22, 1227-1245.	5.7	155
63	Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS-Mutant Lung Cancer. Cancer Discovery, 2013, 3, 548-563.	7.7	153
64	Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Science Translational Medicine, 2019, 11, .	5.8	150
65	Many faces of Ras activation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1786, 178-187.	3.3	149
66	Requirement for Interaction of PI3-Kinase p110Î± with RAS in Lung Tumor Maintenance. Cancer Cell, 2013, 24, 617-630.	7.7	148
67	Fibroblast Growth Factor-2 Induces Translational Regulation of Bcl-XL and Bcl-2 via a MEK-dependent Pathway. Journal of Biological Chemistry, 2002, 277, 12040-12046.	1.6	146
68	RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?. Clinical Cancer Research, 2015, 21, 1802-1809.	3.2	146
69	EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2. Oncogene, 1997, 15, 373-383.	2.6	143
70	Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2183-2194.	1.1	141
71	Matrix detachment induces caspase-dependent cytochrome c release from mitochondria: inhibition by PKB/Akt but not Raf signalling. Oncogene, 2000, 19, 4461-4468.	2.6	135
72	Protein Kinase B Activation and Lamellipodium Formation Are Independent Phosphoinositide 3-Kinase-Mediated Events Differentially Regulated by Endogenous Ras. Molecular and Cellular Biology, 1998, 18, 1802-1811.	1.1	133

#	Article	IF	Citations
73	Regulatory mechanisms forras proteins. BioEssays, 1992, 14, 177-184.	1.2	130
74	Activated R-Ras, Rac1, Pi 3-Kinase and PκcÎμ Can Each Restore Cell Spreading Inhibited by Isolated Integrin Î²1 Cytoplasmic Domains. Journal of Cell Biology, 2000, 151, 1549-1560.	2.3	130
75	Vav3 Modulates B Cell Receptor Responses by Regulating Phosphoinositide 3-Kinase Activation. Journal of Experimental Medicine, 2002, 195, 189-200.	4.2	130
76	ASPP2 controls epithelial plasticity and inhibits metastasis through Î²-catenin-dependent regulationÂofÂZEB1. Nature Cell Biology, 2014, 16, 1092-1104.	4.6	129
77	Interactions of Cbl with Two Adaptor Proteins, Grb2 and Crk, upon T Cell Activation. Journal of Biological Chemistry, 1996, 271, 6159-6163.	1.6	128
78	RASSF1A Interacts with Microtubule-Associated Proteins and Modulates Microtubule Dynamics. Cancer Research, 2004, 64, 4112-4116.	0.4	127
79	PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines. Clinical Cancer Research, 2013, 19, 3533-3544.	3.2	122
80	Human Phosphoinositide 3-Kinase C2Î², the Role of Calcium and the C2 Domain in Enzyme Activity. Journal of Biological Chemistry, 1998, 273, 33082-33090.	1.6	116
81	Binding Specificity and Regulation of the Serine Protease and PDZ Domains of HtrA2/Omi. Journal of Biological Chemistry, 2003, 278, 49417-49427.	1.6	116
82	Lack of Correlation between Activation of Junâ€“NH2-terminal Kinase and Induction of Apoptosis after Detachment of Epithelial Cells. Journal of Cell Biology, 1997, 139, 1017-1023.	2.3	114
83	Cell cycle: Routine role for Ras. Current Biology, 1997, 7, R258-R260.	1.8	114
84	Heregulin Induces Phosphorylation of BRCA1 through Phosphatidylinositol 3-Kinase/AKT in Breast Cancer Cells. Journal of Biological Chemistry, 1999, 274, 32274-32278.	1.6	112
85	Monitoring conformational changes of proteins in cells by fluorescence lifetime imaging microscopy. Biochemical Journal, 2003, 372, 33-40.	1.7	111
86	Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene, 2004, 23, 2431-2441.	2.6	108
87	Autophagy inhibition-mediated epithelialâ€“mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell Death and Disease, 2019, 10, 591.	2.7	107
88	Fibroblast Growth Factor 2-Mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells. Molecular and Cellular Biology, 2003, 23, 7600-7610.	1.1	105
89	Paracrine signalling during ZEB1-mediated epithelialâ€“mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. Cell Death and Differentiation, 2019, 26, 943-957.	5.0	104
90	RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. Cancer Cell, 2019, 36, 68-83.e9.	7.7	104

#	Article	IF	Citations
91	Mechanism of Epidermal Growth Factor Regulation of Vav2, a Guanine Nucleotide Exchange Factor for Rac. Journal of Biological Chemistry, 2003, 278, 5163-5171.	1.6	100
92	Role of RAS in the Regulation of PI 3-Kinase. Current Topics in Microbiology and Immunology, 2010, 346, 143-169.	0.7	99
93	Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells. Autophagy, 2019, 15, 886-899.	4.3	98
94	Involvement of MINK, a Ste20 Family Kinase, in Ras Oncogene-Induced Growth Arrest in Human Ovarian Surface Epithelial Cells. Molecular Cell, 2005, 20, 673-685.	4.5	96
95	The regulation and function of p21ras in T cells. Trends in Immunology, 1992, 13, 89-92.	7.5	95
96	Association of Nck with tyrosine-phosphorylated SLP-76 in activated T lymphocytes. European Journal of Immunology, 1999, 29, 1068-1075.	1.6	95
97	A target for PI(3) kinase. Nature, 1995, 376, 553-554.	13.7	89
98	The Small GTP-binding Protein R-Ras Can Influence Integrin Activation by Antagonizing a Ras/Raf-initiated Integrin Suppression Pathway. Molecular Biology of the Cell, 1999, 10, 1799-1809.	0.9	89
99	Interaction of Ras with phosphoinositide 3-kinase Î³. Biochemical Journal, 1997, 326, 891-895.	1.7	88
100	RNA interference. BMJ: British Medical Journal, 2004, 328, 1245-1248.	2.4	86
101	The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth. Oncogene, 1999, 18, 4586-4597.	2.6	85
102	A Role for p38 Stress-Activated Protein Kinase in Regulation of Cell Growth via TORC1. Molecular and Cellular Biology, 2010, 30, 481-495.	1.1	79
103	Phosphoinositide 3-Kinase C2Î² Regulates Cytoskeletal Organization and Cell Migration via Rac-dependent Mechanisms. Molecular Biology of the Cell, 2006, 17, 3729-3744.	0.9	78
104	Identification of the Ras GTPase-activating protein GAP1m as a phosphatidylinositol-3,4,5-trisphosphate-binding protein in vivo. Current Biology, 1999, 9, 265-269.	1.8	77
105	Chromosomal Instability, Colorectal Cancer and Taxane Resistance. Cell Cycle, 2006, 5, 818-823.	1.3	73
106	Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. Journal of Cell Science, 2002, 115, 2591-2601.	1.2	73
107	Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. Frontiers in Oncology, 2012, 2, 109.	1.3	72
108	SnapShot: Ras Signaling. Cell, 2008, 133, 1292-1292.e1.	13.5	71

#	Article	IF	Citations
109	Regulating 56 kinase. Nature, 1994, 371, 378-379.	13.7	70
110	Targeting RAS and PI3K in lung cancer. Nature Medicine, 2008, 14, 1315-1316.	15.2	68
111	Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway. Oncogene, 2002, 21, 5148-5159.	2.6	67
112	Identification of the E1A-Regulated Transcription Factor p120E4F as an Interacting Partner of the RASSF1A Candidate Tumor Suppressor Gene. Cancer Research, 2004, 64, 102-107.	0.4	67
113	Ras and Phosphoinositide 3-Kinase: Partners in Development and Tumorigenesis. Cell Cycle, 2007, 6, 2902-2905.	1.3	66
114	Chromosomal Instability Selects Gene Copy-Number Variants Encoding Core Regulators of Proliferation in ER+ Breast Cancer. Cancer Research, 2014, 74, 4853-4863.	0.4	66
115	Epithelial to Mesenchymal Transition in Madin-Darby Canine Kidney Cells Is Accompanied by Down-regulation of Smad3 Expression, Leading to Resistance to Transforming Growth Factor-Î²-induced Growth Arrest. Journal of Biological Chemistry, 2003, 278, 3251-3256.	1.6	65
116	RAS interaction with PI3K p110Î± is required for tumor-induced angiogenesis. Journal of Clinical Investigation, 2014, 124, 3601-3611.	3.9	65
117	The Transcriptional Response to Raf Activation Is Almost Completely Dependent on Mitogen-activated Protein Kinase Kinase Activity and Shows a Major Autocrine Component. Molecular Biology of the Cell, 2004, 15, 3450-3463.	0.9	63
118	Roles of cortactin in tumor pathogenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2007, 1775, 263-273.	3.3	62
119	The Grb2 binding domain of mSos1 is not required for downstream signal transduction. Nature Genetics, 1995, 10, 294-300.	9.4	59
120	Full Oncogenic Activities of v-Src Are Mediated by Multiple Signaling Pathways. Journal of Biological Chemistry, 2000, 275, 24096-24105.	1.6	59
121	Signatures guide drug choice. Nature, 2006, 439, 274-275.	13.7	59
122	Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells. Molecular Cancer, 2009, 8, 131.	7.9	58
123	AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons. Scientific Reports, 2018, 8, 8855.	1.6	57
124	Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells. Oncogene, 2004, 23, 8376-8383.	2.6	54
125	Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3KÎ² in myeloid cells. Science Signaling, 2016, 9, ra82.	1.6	53
126	SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Nature Communications, 2019, 10, 2532.	5.8	53

#	Article	IF	Citations
127	Transfer of functional EGF receptors to an IL3-dependent cell line. Journal of Cellular Physiology, 1988, 137, 293-298.	2.0	52
128	Regulation of p21ras by GTPase activating proteins and guanine nucleotide exchange proteins. Current Opinion in Genetics and Development, 1992, 2, 13-18.	1.5	52
129	RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression. Nature Communications, 2016, 7, 11245.	5.8	52
130	KSR: A novel player in the RAS pathway. Cell, 1995, 83, 831-834.	13.5	51
131	Distinct Mechanisms of Î±5Î²1 Integrin Activation by Ha-Ras and R-Ras. Journal of Biological Chemistry, 2000, 275, 22590-22596.	1.6	51
132	Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. PLoS ONE, 2015, 10, e0139074.	1.1	50
133	1 Role of phosphoinositide-3-OH kinase in ras signaling. Advances in Second Messenger and Phosphoprotein Research, 1997, 31, 1-10.	4.5	50
134	Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase. Oncogene, 1998, 17, 691-697.	2.6	48
135	CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploidâ€specific cancer cell death through autophagy induction. Journal of Pathology, 2012, 226, 482-494.	2.1	48
136	Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase gamma. FEBS Journal, 1999, 266, 70-82.	0.2	47
137	Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras. EMBO Journal, 2006, 25, 1093-1103.	3.5	46
138	An oligoclonal antibody durably overcomes resistance of lung cancer to thirdâ€generation <scp>EGFR</scp> inhibitors. EMBO Molecular Medicine, 2018, 10, 294-308.	3.3	46
139	The effector loop and prenylation site of R-Ras are involved in the regulation of integrin function. Oncogene, 2000, 19, 4961-4969.	2.6	45
140	Involvement of survival motor neuron (SMN) protein in cell death. Human Molecular Genetics, 2002, 11, 2751-2764.	1.4	45
141	SIGNAL TRANSDUCTION: Prelude to an Anniversary for the RAS Oncogene. Science, 2006, 314, 433-434.	6.0	45
142	PI3-kinase p110Î± mediates Î²1 integrin-induced Akt activation and membrane protrusion during cell attachment and initial spreading. Cellular Signalling, 2010, 22, 1838-1848.	1.7	45
143	Accumulation of HtrA2/Omi in Neuronal and Glial Inclusions in Brains With Î±-Synucleinopathies. Journal of Neuropathology and Experimental Neurology, 2008, 67, 984-993.	0.9	44
144	Drugging the Undruggable: Advances on RAS Targeting in Cancer. Genes, 2021, 12, 899.	1.0	44

#	Article	IF	Citations
145	Rac and Rho in tune. Nature, 1992, 359, 273-274.	13.7	43
146	Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Medicine, 2010, 2, 53.	3.6	43
147	New exchange, new target. Nature, 1998, 396, 416-417.	13.7	42
148	IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche. Nature Communications, 2020, 11, 764.	5.8	41
149	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nature Communications, 2021, 12, 1780.	5.8	39
150	Metabolism meets death. Nature, 2003, 424, 896-897.	13.7	37
151	Requirement of multiple SH3 domains of Nck for ligand binding. Cellular Signalling, 1999, 11, 253-262.	1.7	36
152	Flicking the Warburg Switchâ€"Tyrosine Phosphorylation of Pyruvate Dehydrogenase Kinase Regulates Mitochondrial Activity in Cancer Cells. Molecular Cell, 2011, 44, 846-848.	4.5	36
153	Praf2 Is a Novel Bcl-xL/Bcl-2 Interacting Protein with the Ability to Modulate Survival of Cancer Cells. PLoS ONE, 2010, 5, e15636.	1.1	36
154	Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. Nature Communications, 2021, 12, 5906.	5.8	36
155	Enhanced HtrA2/Omi Expression in Oxidative Injury to Retinal Pigment Epithelial Cells and Murine Models of Neurodegeneration. , 2009, 50, 4957.		35
156	Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway. CORRELATION WITH RESISTANCE TO ETOPOSIDE-INDUCED APOPTOSIS.. Journal of Biological Chemistry, 2015, 290, 15390.	1.6	34
157	Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer. Science Signaling, 2015, 8, ra53.	1.6	33
158	Role of receptor tyrosine kinases in G-protein-coupled receptor regulation of Ras: transactivation or parallel pathways?. Biochemical Journal, 2003, 376, e9-e10.	1.7	32
159	CUTL1: A Key Mediator of TGFβ-Induced Tumor Invasion. Cell Cycle, 2006, 5, 132-134.	1.3	32
160	SnapShot: Class I PI3K Isoform Signaling. Cell, 2013, 154, 940-940.e1.	13.5	32
161	Modulation of Cellular Migration and Survival by c-Myc through the Downregulation of Urokinase (uPA) and uPA Receptor. Molecular and Cellular Biology, 2010, 30, 1838-1851.	1.1	30
162	YAP and p73: A Complex Affair. Molecular Cell, 2008, 32, 749-750.	4.5	28

#	Article	IF	Citations
163	Translational responses to growth factors and stress. Biochemical Society Transactions, 2009, 37, 284-288.	1.6	28
164	Frank-ter Haar Syndrome Protein Tks4 Regulates Epidermal Growth Factor-dependent Cell Migration. Journal of Biological Chemistry, 2012, 287, 31321-31329.	1.6	28
165	Interleukin (IL)-2 activation of p21ras in murine myeloid cells transfected with human IL-2 receptor Î² chain. European Journal of Immunology, 1992, 22, 817-821.	1.6	27
166	Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer. Cell Discovery, 2016, 2, 16031.	3.1	26
167	Targeting RAF: trials and tribulations. Nature Medicine, 2011, 17, 286-288.	15.2	25
168	Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer. Cell Reports, 2018, 25, 3545-3553.e2.	2.9	25
169	Exchange rate mechanisms. Nature, 1992, 358, 282-283.	13.7	24
170	CUTL1 Is Phosphorylated by Protein Kinase A, Modulating Its Effects on Cell Proliferation and Motility. Journal of Biological Chemistry, 2006, 281, 15138-15144.	1.6	24
171	Bidirectional epithelialâ€“mesenchymal crosstalk provides self-sustaining profibrotic signals in pulmonary fibrosis. Journal of Biological Chemistry, 2021, 297, 101096.	1.6	24
172	Antibodies to the ATP-binding site of the human epidermal growth factor (EGF) receptor as specific inhibitors of EGF-stimulated protein-tyrosine kinase activity. FEBS Journal, 1986, 158, 245-253.	0.2	23
173	Ras regulation: putting back the GTP. Current Biology, 1992, 2, 329-331.	1.8	23
174	Stimulation of gene expression in neonatal rat ventricular myocytes by Ras is mediated by Ral guanine nucleotide dissociation stimulator (Ral.GDS) and phosphatidylinositol 3-kinase in addition to Raf. Biochemical Journal, 1998, 335, 241-246.	1.7	23
175	Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-Î². Journal of Cell Science, 2009, 122, 1917-1926.	1.2	23
176	Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids. Carcinogenesis, 2014, 35, 396-406.	1.3	23
177	HFâ€Free Boc Synthesis of Peptide Thioesters for Ligation and Cyclization. Angewandte Chemie - International Edition, 2016, 55, 13174-13179.	7.2	23
178	SGLT1 is required for the survival of tripleâ€negative breast cancer cells via potentiation of EGFR activity. Molecular Oncology, 2019, 13, 1874-1886.	2.1	22
179	JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer. JCI Insight, 2021, 6, .	2.3	22
180	A tumour gene's fatal flaws. Nature, 2009, 462, 44-45.	13.7	21

#	Article	IF	Citations
181	RASâ€™s Cloak of Invincibility Slips at Last?. Cancer Cell, 2014, 25, 5-6.	7.7	21
182	Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Research, 2008, 10, 214.	2.2	20
183	Genetic and cellular mechanisms of oncogenesis. Current Opinion in Genetics and Development, 2009, 19, 1-3.	1.5	20
184	Inhibiting the RASâ€“PI3K Pathway in Cancer Therapy. The Enzymes, 2013, 34 Pt. B, 107-136.	0.7	20
185	Mutant KRAS at the Heart of Tumor Immune Evasion. Immunity, 2020, 52, 14-16.	6.6	20
186	Regulation ofMUC1Expression in Human Mammary Cell Lines by the c-ErbB2 and Ras Signaling Pathways. DNA and Cell Biology, 2001, 20, 265-274.	0.9	19
187	Exoenzyme S of Pseudomonas aeruginosa is not able to induce apoptosis when cells express activated proteins, such as Ras or protein kinase B/Akt. Cellular Microbiology, 2006, 8, 815-822.	1.1	19
188	WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer. Cell Death and Disease, 2020, 11, 1001.	2.7	19
189	Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. Science Translational Medicine, 2021, 13, .	5.8	19
190	<scp>RAS</scp> mutation status and bortezomib therapy for relapsed multiple myeloma. British Journal of Haematology, 2015, 169, 905-908.	1.2	18
191	Combined targeting of G proteinâ€coupled receptor and <scp>EGF</scp> receptor signaling overcomes resistance to <scp>PI</scp> 3K pathway inhibitors in <scp>PTEN</scp> â€null triple negative breast cancer. EMBO Molecular Medicine, 2020, 12, e11987.	3.3	17
192	[11] Measurement of nucleotide exchange and hydrolysis activities in immunoprecipitates. Methods in Enzymology, 1995, 255, 110-117.	0.4	16
193	RNA Interference Libraries Prove Their Worth in Hunt for Tumor Suppressor Genes. Cell, 2005, 121, 813-815.	13.5	16
194	Apoptosis:. Current Biology, 1999, 9, R176-R179.	1.8	15
195	Ras activation of phosphatidylinositol 3-kinase and akt. Methods in Enzymology, 2001, 333, 37-44.	0.4	15
196	Initiation of High Frequency Multi-Drug Resistance Following Kinase Targeting by siRNAs. Cell Cycle, 2007, 6, 2001-2004.	1.3	14
197	Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets. Wellcome Open Research, 2020, 5, 20.	0.9	14
198	[17] Measurements of GTP/GDP exchange in permeabilized fibroblasts. Methods in Enzymology, 1995, 255, 156-161.	0.4	13

#	Article	IF	Citations
199	Unraveling the Complexity of Endocrine Resistance in Breast Cancer by Functional Genomics. Cancer Cell, 2008, 13, 83-85.	7.7	12
200	Overview of KRASâ€Driven Genetically Engineered Mouse Models of Nonâ€Small Cell Lung Cancer. Current Protocols in Pharmacology, 2015, 70, 14.35.1-14.35.16.	4.0	12
201	Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13156-13161.	3.3	12
202	RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?. Lancet Oncology, The, 2004, 5, 653-654.	5.1	11
203	ATMIN Is a Tumor Suppressor Gene in Lung Adenocarcinoma. Cancer Research, 2019, 79, 5159-5166.	0.4	10
204	Finding the Weakness in Cancer. New England Journal of Medicine, 2009, 361, 922-924.	13.9	7
205	Plugging the GAPs. Current Biology, 1991, 1, 353-355.	1.8	6
206	RNA interference-based functional genomics in cancer research â€“ an introduction. Oncogene, 2004, 23, 8334-8335.	2.6	6
207	How to Fool a Wonder Drug: Truncate and Dimerize. Cancer Cell, 2012, 21, 7-9.	7.7	5
208	Quantitative Proteomic Analysis in Alveolar Type II Cells Reveals the Different Capacities of RAS and TGF-Î² to Induce Epithelialâ€“Mesenchymal Transition. Frontiers in Molecular Biosciences, 2021, 8, 595712.	1.6	5
209	Inherited duplications of PPP2R3B predispose to nevi and melanoma via a C21orf91-driven proliferative phenotype. Genetics in Medicine, 2021, 23, 1636-1647.	1.1	5
210	Ras activation revisited. Signal Transduction, 2001, 1, 11-24.	0.7	4
211	Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Scientific Reports, 2022, 12, 2699.	1.6	4
212	Concordance of exon array and real-time PCR assessment of gene expression following cancer cell cytotoxic drug exposure. Cell Cycle, 2008, 7, 3947-3948.	1.3	3
213	HFâ€Free Boc Synthesis of Peptide Thioesters for Ligation and Cyclization. Angewandte Chemie, 2016, 128, 13368-13373.	1.6	3
214	Trachealessâ€”A New Transcription Factor Target for PKB/Akt. Developmental Cell, 2001, 1, 726-728.	3.1	2
215	Assessing Cell Size and Cell Cycle Regulation in Cells with Altered TOR Activity. Methods in Molecular Biology, 2012, 821, 227-237.	0.4	1
216	The Potency of a KRAS Silent Variant. New England Journal of Medicine, 2022, 386, 2523-2525.	13.9	1

#	Article	IF	Citations
217	RNAi and 2DE, a promising combination for analysis of phospho-signalling and substrate identification. International Journal of Peptide Research and Therapeutics, 2003, 10, 437-445.	0.1	0
218	mTORC2. The Enzymes, 2010, 28, 99-124.	0.7	0
219	Automated segmentation of murine lung tumors in x-ray micro-CT images. Proceedings of SPIE, 2014, , .	0.8	0
220	Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets. Wellcome Open Research, 0, 5, 20.	0.9	0